15001-09-9

Basic information

• Product Name: ethyl 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxylate
• Synonyms: ethyl 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxylate
• CAS NO: 15001-09-9
• Molecular Formula: C₁₃H₁₅N₃O₂
• Molecular Weight: 245.2771
• Mol File: 15001-09-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxylate(15001-09-9)
• EPA Substance Registry System: ethyl 5-amino-1-(2-methylphenyl)-1H-pyrazole-4-carboxylate(15001-09-9)

Safety Data

• Hazardous Substances Data: 15001-09-9(Hazardous Substances Data)

Upstream product

• 635-26-7 o-tolylhydrazine hydrochloride 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 529-27-1 2-methylphenylhydrazine 
• 68350-76-5 2-cyano-3-methoxyacrylic acid ethyl ester 

Downstream Products

• 14678-98-9 1-(2-methylphenyl)-1H-pyrazol-5-amine 

Relevant articles and documents

Targeting Pim Kinases and DAPK3 to Control Hypertension

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: Role of the chirality on the biological activity

An asymmetric synthetic strategy was designed for the preparation of the four possible diastereoisomers of 3,6-dimethyl-1-(2-methylphenyl)-4-(4- phenoxyphenyl)-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7-one, a non-steroidal FXR agonist, we recently discovered following a virtual screening approach. The results obtained from an AlphaScreen assay clearly demonstrated that only the isomer endowed with 4R,6S absolute configuration is responsible for the biological activity. A deep investigation of the different putative binding modes adopted by these enantiomerically pure ligands using computational modeling studies confirmed the enantioselectivity of FXR towards this class of molecules.